Risk factor control and treatment of atherothrombosis. Spain REACH Registry;Control de factores de riesgo y tratamiento de la aterotrombosis. Registro REACH España

Medicina Clinica

Volumn 129, Issue 12, 2007, Pages 446-450

  Suárez, Carmen ^a   Cairols, Marc ^b   Castillo, José ^c   Esmatjes, Enric ^d   Sala, Joan ^e   Llobet, Xavier ^f   Palma, Juan Carlos ^g  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f Centro de Investigation Basica Sanofi Aventis   (Spain)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Atherothrombosis; Primary prevention; Risk factors; Secondary prevention; Use of medicines

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COMORBIDITY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

EID: 36048965856     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13111002     Document Type: Article

References (24)

1. Viles-González JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197-207.
2. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF III, Graor RA, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984;199:223-33.
3. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol. 1994;74:64-5.
4. Yusuf S, Hawken S, Ounupu S, Dans T, Avezum A, Lanas F, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-controlled study. Lancet. 2004;364:937-52.
5. Álvarez-Sala LA, Suárez C, Mantilla T, Franch J, Ruilope LM, Banegas JR, et al; Grupo PREVENCAT. Estudio PREVENCAT: control del riesgo cardiovascular en atención primaria. Med Clin (Barc). 2005;124:406-10.
6. Coca A, Dalfó A, Esmatjes E, Llisterri JL, Ordóñez J, Gomis R, et al; en representación del grupo PREVENCAT. Tratamiento y control del riesgo cardiovascular en atención primaria en España. Estudio PREVENCAT. Med Clin (Barc). 2006; 126:201-5.
7. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al; for the REACH registry investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295:180-9.
8. World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens. 1999;17:151-83.
9. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601-10.
10. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, Conthe P, et al; Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC). Adaptación española de la Guía Europea de Prevención Cardiovascular. Clin Invest Arterioscl. 2005;17:19-33.
11. Martínez JA, Kearney JM, Kafatos A, Paquet S, Martínez- González MA. Variables independently associated with self-reported obesity in the European Union. Public Health Nutr. 1999;2:125-33.
12. De la Peña Fernández A, Suárez Fernández CM, Cuende Melero I, Muñoz Rodríguez M, Garre Canovas J, Camafort Babkowski M, et al. Control integral de los factores de riesgo en pacientes de alto y muy alto riesgo cardiovascular en España (estudio CIFARC). Med Clin (Barc). 2005;124: 44-9.
13. Seculi E, Brugulat P, Medina A, Junca S, Tresserras R, Salleras L. Detección de factores de riesgo cardiovascular en la red reformada de atención primaria en Cataluña. Comparación entre los años 1995 y 2000. Aten Primaria. 2003;31:156-62.
14. Cuende JI, Acebal A, Abad Fernández JL, Álvarez López J, De Miguel Gutiérrez A, Triana Sánchez JM, et al. Percentiles de riesgo: un nuevo método adaptado para la valoración del riesgo vascular. Estudio ERVPA. Med Clin (Barc). 2004; 123:121-6.
15. De Velasco JA, Cosín J, López-Sendón JL, De Teresa E, De Oya M, Sellers G, en representación del grupo de investigadores del estudio PREVESE II. Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESE II. Rev Esp Cardiol. 2002;55:801-9.
16. Willigendael EM, Teijink JA, Bartelink ML, Kuiken BW, Boiten J, Moll FL, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004;40: 1158-65.
17. Llisterri JR, Rodríguez G, Alonso FJ, Lou S, División JA, Santos JA, et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2002. Med Clin (Barc). 2004;122: 165-71.
18. Coca Payeras A. Evolución del control de la hipertensión arterial en Atención Primaria en España. Resultados del estudio Controlpres 2003. Hipertensión. 2005;22:5-14.
19. Banegas Banegas JR. Epidemiología de la hipertensión arterial en España. Situación actual y perspectivas. Hipertensión. 2005;22:353-62.
20. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol. 1994;74:64-5.
21. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherotrombosis. N Engl J Med. 2005;353: 2373-83.
22. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. REVSERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA. 2004;291:1071-80.
23. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.
24. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DM, et al; Coordinating Committee of the National Cholestrol Education Program. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidlines. Arterioscler Thromb Vasc Biol. 2004; 24:1329-30.